MedTrace Logo

Autologous Killer Cell Therapy in Colon Cancer Patients

NCT03329664 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2021-03-15

No results posted yet for this study

Summary

This study aims to evaluate the safety and efficacy of activated and expanded autologous cytokine-killer cells in controlling disease recurrence in colon cancer patients with liver metastasis. 20 patients with confirmed stage IV colon carcinoma with metastasis will be assigned into two groups. Patients in both groups will receive the same therapeutic regimen as usual. Patients in one group additionally will be treated with a single infusion of autologous killer cells that had been previously prepared from peripheral blood.

Conditions

  • Colon Cancer Stage IV

Interventions

BIOLOGICAL

Cytokine-induced killer cell

Immune-cell therapy with CIK cells

OTHER

Chemotherapy AND/OR Radiation Therapy

Routine treatments for colon cancer patients according to their stage

Sponsors & Collaborators

  • Ministry of Health and Medical Education

    collaborator UNKNOWN

  • Digestive Diseases Research Institute, Tehran University of Medical Sciences, Iran

    collaborator UNKNOWN

  • Sabz Biomedicals

    lead INDUSTRY

Principal Investigators

  • Naser Ahmadbeigi, Ph.D · Cell-based Therapies Research Center, Digestive Disease Research Institute, Tehran University of Medical Sciences, Tehran, Iran

Study Design

Allocation
NON_RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-09
Primary Completion
2021-09-30
Completion
2022-01-31

Countries

  • Iran

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03329664 on ClinicalTrials.gov